This popular drink may increase the risk of blood cancer, warn doctors
Taurine, long hailed as a performance-boosting ingredient in many common energy drinks, is now under fresh scientific scrutiny as a new study has raised red flags about its potential link to blood cancers, particularly leukemia.
Tired of too many ads? go ad free now
Researchers at the University of Rochester's Wilmot Cancer Institute explained that leukemia cells may exploit taurine, which develops in bone marrow, to fuel their growth through a process called glycolysis. The process enables cells to break down glucose to produce energy, which cancer cells use to grow.
This new finding has prompted urgent questions about the safety of excessive taurine intake through supplements and beverages.
Taurine is usually found in animal proteins, specifically meat, seafood, and dairy products. In energy drinks, it is added to improve mental performance and reduce inflammation. It is also used to relieve chemotherapy side effects in leukemia patients. According to a study published in the Journal of Cancer Research and Therapeutic, 'taurine supplementation could be a protection against chemotherapy-induced toxicities probably by its antioxidant capacity.
'
While in moderation, this compound is useful, its excessive intake, whether through supplements or energy drinks could increase leukemia risk by way of fueling the cancer cells.
How the study was conducted
The study focused on mice with a specific gene called SLC6A6, which plays a key role in transporting taurine throughout the body.
Researchers introduced human leukemia cells into these mice to observe how they would respond. They found that healthy bone marrow cells naturally produce taurine, and the SLC6A6 gene helps move this taurine to the leukemia cells, potentially aiding their growth.
Tired of too many ads? go ad free now
Given how commonly taurine is consumed through energy drinks and supplements, the researchers stressed the importance of carefully weighing the potential risks and benefits, especially for leukemia patients and regular energy drink users.
Researchers are of the view that blocking taurine in leukemia cells could lead to development of new treatment options. The researchers eventually also want to find out whether taurine can also contribute to the spike of other cancers, such as colorectal cancer.
'As taurine is a common ingredient in energy drinks, and is often provided as a supplement to mitigate the side-effects of chemotherapy our work suggests that it may be of interest to carefully consider the benefits of supplemental taurine in patients with leukaemia," researchers wrote in Nature.
Drinking coffee may cut womb cancer risk
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
a day ago
- Time of India
What is Legionnaires' disease? Know causes, symptoms, risk factors, prevention and more
Image credits: Getty Images Legionnaires' disease is a form of pneumonia caused by inhaling water droplets contaminated with Legionella bacteria, scientifically called Legionella pneumophila. Recently, an outbreak of the disease in Harlem, New York, has led to the death of one person and sickened 22 more. According to the Centers for Disease Control and Prevention (CDC), about 8,000 to 18,000 people are hospitalized with the disease in the US annually. Here's all you need to know about the disease. Causes of Legionnaires' disease Image credits: X Legionella bacteria are intracellular, aerobic bacteria that are the agent of Legionnaires' disease. They are commonly found in lakes, rivers, creeks, hot springs, and other bodies of water and grow at temperatures of 20 to 50 degrees Celsius. The bacteria was first identified in 1977 as the cause of an outbreak of severe pneumonia in a convention centre in the USA in 1976. The disease is transmitted due to the inhalation of aerosols from contaminated water containing the bacteria. The sources can be air conditioning cooling towers, hot and cold water systems, humidifiers and whirlpool spas, as per the World Health Organization. Symptoms of Legionnaires' disease Image credits: Getty Images According to the National Library of Medicine, Legionnaires' disease is a severe infection with high complication and mortality rates that requires immediate hospitalization. It has two forms- non-pneumonic (Pontiac disease) and pneumonic. The non-pneumonic is an influenza-like illness that lasts for 2-5 days with an incubation period from a few and up to 48 hours. The symptoms of this can be fever, chills, headache, and muscle pain. It is non-fatal. The pneumonic form has an incubation period of 2-10 days and has symptoms such as fever, loss of appetite, headache, malaise, lethargy, diarrhea and confusion. There is also an initial mil cough. This can be fatal with the pneumonia progressing and leading to respiratory failure and/or multi-organ failure. Who is at risk of Legionnaires' disease? People who are healthy and come in contact with the bacteria don't fall sick. However, those above the age of 50, who have a history or present of smoking, have a lung disease and a weakened immune system, and can be susceptible to bacteria quickly. Treatment of Legionnaires' disease Image credits: Getty Images While the treatment for the disease exists, there is currently no vaccine for it. It can be diagnosed with the help of a chest X-ray to see if you have been infected. Then tests such as urine or sputum tests can be made to confirm the presence of bacteria. Prevention of Legionnaires' disease The prevention of the disease relies on the control of the growth of the bacteria and the spread of the aerosols. This includes proper maintenance of cooling towers, maintaining an adequate level of biocide such as chlorine in waters, keeping hot and cold water systems clean and flushing unused taps on a weekly basis.
Hindustan Times
2 days ago
- Hindustan Times
Kerala Medical Services Corporation not procured rabies jabs without CDL certificate: Nadda
New Delhi, Union Health Minister J P Nadda told the Lok Sabha on Friday that the Kerala Medical Services Corporation has not procured or distributed any batch of rabies vaccine or equine anti-rabies immunoglobulin without a batch release certificate from the Central Drugs Laboratory . Kerala Medical Services Corporation not procured rabies jabs without CDL certificate: Nadda He was responding to a question whether the manufacturers supplying anti-rabies vaccine to KMSCL had done the mandatory tests from the CDL during the last five years and the current year. "As informed by Kerala Medical Services Corporation , all Rabies Vaccines and Equine Anti-Rabies Immunoglobulins procured and distributed by them from the tender year 2016-17 onwards have obtained Batch Release Certificates from Central Drugs Laboratory , Kasauli, as mandated in the tender terms and conditions," Nadda said. "KMSCL has not procured or distributed any batch of Rabies vaccine or Equine Anti-rabies Immunoglobulin without a batch release certificate from CDL," Nadda said. For the manufacturing or import of new drugs, including vaccines, the manufacturers and importers are required to comply with the standards of quality, safety and efficacy as prescribed in the Drugs and Cosmetics Act, 1940 and Rules. The mandatory quality requirements prescribed to ensure the quality of anti-rabies vaccines being manufactured in the country include a manufacturing licence and import licence issued under the Drugs and Cosmetics Act and Rules and that the anti-rabies vaccine must comply with the standards specified in the current edition of the Indian Pharmacopoeia. Each batch must undergo complete in-house quality control testing at the manufacturer's facility according to validated procedures and IP standards. Each batch or lot of vaccines manufactured or imported in the country is required to be released by the CDL at Kasauli in Himachal Pradesh before the release of vaccines for sale and distribution, Nadda explained. He said that proper cold chain logistics, two degrees Celsius to eight degrees Celsius must be maintained throughout storage and transportation to preserve vaccine potency and vaccines must have a valid remaining shelf life at the time of supply and should be packaged to ensure protection during transit and storage. According to Rule 2 of New Drugs and Clinical Trial Rules, 2019, vaccines are always deemed to be new drugs. All manufacturers of vaccines have to comply with the conditions of mandatory quality tests apart from other conditions of licence as prescribed under Rules 78 and 78A of Drug Rules, 1945 and both the Central License Approving Authority and state licensing authorities are empowered to take stringent action against violation of provisions of the Act and Rules. This article was generated from an automated news agency feed without modifications to text.
Deccan Herald
2 days ago
- Deccan Herald
Virtual labs with AI scientists show promise: Stanford study
Virtual scientists in a virtual lab at Stanford University are coming up with unorthodox ways to address clinical challenges, researchers reported on Tuesday in Nature. The virtual lab is modeled after a well-established Stanford School of Medicine research group, complete with a principal investigator and seasoned scientists, the report says. As in human-run research labs, the virtual lab has regular meetings during which agents generate ideas and engage in a conversational back-and-forth. They also have one-on-one meetings, allowing the virtual lab members to meet with the virtual principal investigator individually to discuss ideas. Unlike human meetings, the virtual gatherings take a few seconds or minutes. When humans tasked the virtual team with devising a better vaccine for the SARS-CoV-2 virus that causes COVID-19, they equipped the virtual scientists with tools and software to stimulate creative 'thinking' skills. The virtual scientists even created their own wish list. 'They would ask for access to certain tools, and we'd build it into the model to let them use it,' study leader James Zou said in a statement. Instead of opting for the usual vaccine design using an antibody, the AI team came up with using a nanobody, an antibody fragment that's smaller and simpler. 'From the beginning of their meetings, the AI scientists decided that nanobodies would be a more promising strategy,' Zou said. 'They said nanobodies are typically much smaller than antibodies, so that makes the machine learning scientist's job much easier," Zou said, "because when you computationally model proteins, working with smaller molecules means you can have more confidence in modeling and designing them.' When humans created the AI researchers' nanobody in a real-world lab, they found it was stable and could attach itself to one of the COVID virus variants more tightly than existing antibodies - a key factor in determining vaccine effectiveness. Aside from the initial prompt, the main guideline consistently given to the AI lab members was budget-related. Zou estimates that he or his lab members intervene about 1% of the time. 'I don't want to tell the AI scientists exactly how they should do their work. That really limits their creativity,' Zou said. 'I want them to come up with new solutions and ideas that are beyond what I would think about.'
